Financial conflict of interest in clinical psychiatry studies: A review

Turk Psikiyatri Dergisi

Volumn 19, Issue 4, 2008, Pages

  Ulaş, Halis ^b   Binbay, Tolga ^b   Alptekin, Köksal ^a  

^a H LUNDBECK A S   (Denmark)

^b NONE

Author keywords

Bias; Conflict of interest; Drug industry; Psychiatry; Psychopharmacology

Indexed keywords

EID: 63249103935     PISSN: 13002163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. AAMC Task Force on Financial Conflicts of interest in Clinical Research (2003). Protecting subjects, preserving trust, promoting progress I: Policy and guidelines for the oversight of individual financial interests in human subjects research. Acad Med, 78: 225-236.
2. Ahmer S, Arya P, Anderson D et al. (2005) Conflict of interest in psychiatry. Psychiatr Bull, 29: 302-304.
3. Akşit B ve Arda B (2003) Ideas of editors of medical journals on publication ethics. J Ankara Med Sch, 25: 1-6.
4. Als-Nielsen B, Chen W, Gluud C et al. (2003) Association of funding and conclusions in randomized drug trials: A reflection of treatment effect or adverse events? JAMA, 290: 921-928.
5. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Washington DC: American Psychiatric Press.
6. Angell M (2000) Is academic medicine for sale? N Engl J Med, 342: 1516-1518.
7. Blumenthal D, Campbell EG, Anderson MS et al. (1997) Withholding research results in academic life science: evidence from a national survey of faculty. JAMA, 277: 1224 -1228.
8. Bondolfi G, Dufour H, Patris M et al. (1998) Risperidone versus clozapine in treatment resistant chronic schizophrenia. Am J Psychiatry, 155: 499-504.
9. Bushfield J (2003) The pharmaceutical industry: Globalization and the pharmaceutical industry revisited. Int J Health Serv, 33: 581-605.
10. Chouinard G, Jones B, Remington G et al. (1993) A Canadian multi-center placebo-controlled study of fixed doses of risperidone and halperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol, 13: 25-40.
11. Choundry NK, Stelfox HK, Allan D (2002) Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA, 287: 612-617.
12. Cosgrove L, Krimsky S, Vijayaraghvan M et al. (2006) Financial ties between DSM-IV panel members and the pharmaceutical industry. Psychother Psychosom, 75: 154-160.
13. Council on Scientific Affairs (1990) Conflicts of interest in medical center/industry research relationships. JAMA, 263: 2790-2793.
14. Çekin MD, Yazici S (2000) Drug investigations as a quasi-science (Article in Turkish). Public and Physician, 19: 110-116.
15. Davidoff F, DeAngelis CD, Drazen JM et al. (2001). Sponsorship, authorship, and accountability. JAMA, 286:1232-1234. Davidson RA (1986) Source of funding and outcome of clinical trials. J Gen Intern Med, 1: 155-158.
16. Djulbegovic B, Lacevic M, Cantor A et al. (2000) The uncertainty principle and industry sponsored research. Lancet, 356: 635-638.
17. Fava GA (2007) Financial conflicts of interest in psychiatry. World Psychiatry, 6: 19-24.
18. Flanagin A, Carey LA, Fontanarosa PB et al. (1998) Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA, 280: 222-224.
19. Fontanarosa PN, Flanagin A, de Angelis CD (2005) Reporting conflicts of interest, financial aspects of research, and role of sponsors in funded studies. JAMA, 294: 110-111.
20. Freemantle N, Anderson I, Young P (2000) Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs: Metaregression analysis. Br J Psychiatry, 177: 292-302.
21. Gøtzsche PC, Hrobjartsson A, Johansen HK et al. (2007) Ghost authorship in industry initiated randomised trials. PLoS Med, 4: e19.
22. Gupta P ve Choudhury P (2003) Declaring competing interests. Indian Pediatr, 40: 3-6.
23. Haddad PM, Dursun S (2006) Selecting antipsychotics in schizophrenia: Lessons from CATIE. J Psychopharmacol, 20: 332-334.
24. Hardell L, Walker MJ, Walhjalt B et al. (2007) Secret ties to industry and conflicting interests in cancer research. Am J Ind Med, 50: 227-233.
25. Healy DI (2002) Conflicting interests in Toronto: Anatomy of a controversy at the interface of academia and industry. Perspect Biol Med, 45: 250-263.
26. Heres S, Davis J, Maino K et al. (2006) Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of secondgeneration antipsychotics. Am J Psychiatry, 163: 185-194.
27. Huston P, Moher D (1996) Redundancy, disaggregation, and the integrity of medical research. Lancet, 347: 1024-1026.
28. Huth EJ (1986) Irreponsible authorship and wasteful publication. Ann Intern Med; 104: 257-259.
29. Jones PB, Barnes TRE, Davies L et al. (2006) Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry, 63: 1079-1087.
30. Kelly RE Jr, Cohen LJ, Semple RJ et al. (2006) Relationship between drug company funding and outcomes of clinical psychiatric research. Psychol Med, 36: 1647-1656.
31. Kessler DA (1992) Addressing the problem of misleading advertising. Ann Intern Med, 116: 950-951.
32. Krimsky S, Rothenberg LS, Stott P et al. (1998) Scientific journals and their authors' financial interests: a pilot study. Psychother Psychosom, 67: 194-201
33. Lapierre YD, Nair NP, Chouinard G et al. (1990) A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia - a Canadian multicentre trial. Acta Psychiatr Scand, 82 (Suppl 358): s72-s76.
34. Lieberman JA, Stroup TS, McEvoy JP et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 353: 1209-1223.
35. Lieberman JA (2007) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry, 68: e04.
36. Marder SR (1999) Newer antipsychotics in treatment-resistant schizophrenia. Biol Psychiatry, 45: 383-384.
37. Melander H, Rastad JA, Meijer G et al. (2003) Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: Review of studies in new drug applications. BMJ, 326: 1171-1173.
38. Miller AL, Hall CS, Buchanan RW et al. (2004) The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry, 65: 500-508.
39. Moncrieff, J. (2003) Clozapine vs. conventional antipsychotic drugs for treatment-resistant schizophrenia: A re-examination. Br J Psychiatry, 183: 161-166.
40. Montaner JS, O'Shaughnessy MV, Schechter MT (2001) Industry-sponsored clinical research: A double-edged sword. Lancet, 358: 1893-1895.
41. Montgomery JH, Byerly M, Carmody T et al. (2004) An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Control Clin Trials, 25: 598-612.
42. Mowatt G, Shirran L, Grimshaw JM et al. (2002) Prevalence of honorary and ghost authorship in Cochrane reviews. JAMA, 287: 2769-2771.
43. Nierenberg AA (2007) A counter proposal to manage financial conflicts of interest in academic psychiatry. World Psychiatry, 6: 34-36.
44. Patris M, Agussol P, Alby JM et al. (1990) A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol. Acta Psychiatr Scand, 82 (Suppl 358): s78-s82.
45. Perlis RH, Perlis CS, Wu Y et al. (2005) Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry, 162: 1957-1960.
46. Purdon SE, Jones BD, Stip E et al. (2000) Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry, 57: 249-258.
47. Rampton S, Stauber J (2002) Research funding, conflict of interest, and the meta-methodology of public relations. Public Health Rep, 117: 331-339.
48. Rennie D (1997) Thyroid storm. JAMA, 277: 1238-1243.
49. Rubin EH (2005) The complexities of individual financial conflicts of interest. Neuropsychopharmacology, 30: 1-6.
50. Safer DJ (2002) Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis, 190: 583-592.
51. Sechter D, Peuskens J, Fleurot O et al. (2002) Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology, 27: 1071-1081.
52. Simpson GM, Lindenmeyer JP (1997) Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol, 17: 194-201.
53. Tohen M (2007) Conflicts of interest and the credibility of psychiatric research. World Psychiatry, 6: 33-34.
54. Van Amum P (2006) Global pharmaceutical market shows moderate growth. Pharmaceutical Technology, 30: 32.
55. Warner TD, Gluck JP (2003) What do we really know about conflicts of interest in biomedical research? Psychopharmacology, 171: 36-46.